The company anticipates submission for emergency use authorisation (EUA) to the
The global Phase II clinical trial is a randomised, double-blind, placebo-controlled and parallel-group trial designed to evaluate the efficacy and safety of CT-P59 in combination with standard-of-care in patients with SARS-CoV-2 infection.
The trial enrolled 327 patients with mild-to-moderate symptoms of COVID-19 across three groups (placebo, low concentration and high concentration). In addition,
"We managed to successfully enrol 327 patients for the global Phase II trial and the results from the trial are expected in the coming weeks. We plan to compile a robust data set to support the planned EUA, expected as early as the end of the year, subject to positive study results," said Dr
Sputnik V COVID-19 vaccine over 90 percent effective, interim data shows…
In an effort to further address the pandemic,
The company is also working to increase its manufacturing capabilities to meet the current global and domestic demand for the anti-COVID-19 mAb treatment candidate, ensuring potential delivery for as many as two million people per year globally.
The post Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2020. All Rights Reserved., source